Literature DB >> 1984461

Infectivity of Borrelia burgdorferi correlates with resistance to elimination by phagocytic cells.

K Georgilis1, A C Steere, M S Klempner.   

Abstract

The Lyme disease spirochete, Borrelia burgdorferi, causes a disseminated infection in vivo, implying resistance to clearance by phagocytic cells. Because B. burgdorferi loses its infectivity after in vitro cultivation, the relationships between serial passaging of the organism in vitro, its susceptibility to elimination by phagocytes, and its infectivity were examined. When three different high-passage strains were incubated for 4 h at 37 degrees C with peripheral blood mononuclear cells, macrophages, or polymorphonuclear neutrophils, 45%-67% of the organisms were eliminated. In contrast, two low-passage strains were resistant to elimination by phagocytes, and only 5%-6% of the organisms were removed after 4 h. All five strains equally stimulated the neutrophil oxidative burst, indicating that evasion of phagocytes was not a result of avoidance of recognition by these cells. The two low-passage strains were infective when injected into mice, whereas the three high-passage ones were not. These observations indicate that infectivity of the Lyme disease spirochete correlates with resistance to elimination by phagocytic cells.

Entities:  

Mesh:

Year:  1991        PMID: 1984461     DOI: 10.1093/infdis/163.1.150

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Functional analysis of Borrelia burgdorferi uvrA in DNA damage protection.

Authors:  Mariya Sambir; Larisa B Ivanova; Anton V Bryksin; Henry P Godfrey; Felipe C Cabello
Journal:  FEMS Microbiol Lett       Date:  2011-02-17       Impact factor: 2.742

2.  Coiling phagocytosis is the preferential phagocytic mechanism for Borrelia burgdorferi.

Authors:  M G Rittig; A Krause; T Häupl; U E Schaible; M Modolell; M D Kramer; E Lütjen-Drecoll; M M Simon; G R Burmester
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

3.  Macrophages exposed to Borrelia burgdorferi induce Lyme arthritis in hamsters.

Authors:  B K Du Chateau; D M England; S M Callister; L C Lim; S D Lovrich; R F Schell
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 4.  Host-pathogen interactions in the immunopathogenesis of Lyme disease.

Authors:  L T Hu; M S Klempner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

5.  Borrelia burgdorferi organisms lacking plasmids 25 and 28-1 are internalized by human blood phagocytes at a rate identical to that of the wild-type strain.

Authors:  Samiya Al-Robaiy; Jens Knauer; Reinhard K Straubinger
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  Depletion of complement and effects on passive transfer of resistance to infection with Borrelia burgdorferi.

Authors:  J L Schmitz; S D Lovrich; S M Callister; R F Schell
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

7.  Platelet-activating-factor-mediated pathogenesis in Lyme disease.

Authors:  E Isogai; K Kimura; N Fujii; T Nishikawa; N Ishii; D Postic; G Baranton; H Isogai
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

8.  Intracellular persistence of Borrelia burgdorferi in human synovial cells.

Authors:  H J Girschick; H I Huppertz; H Rüssmann; V Krenn; H Karch
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

9.  Macrophages and enriched populations of T lymphocytes interact synergistically for the induction of severe, destructive Lyme arthritis.

Authors:  B K DuChateau; J R Jensen; D M England; S M Callister; S D Lovrich; R F Schell
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

10.  Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist.

Authors:  L C Miller; S Isa; E Vannier; K Georgilis; A C Steere; C A Dinarello
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.